- Home
- ALOT vs AGEN Comparison
ALOT vs AGEN Comparison
Compare ALOT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALOT
- AGEN
- Stock Information
- Founded
- ALOT 1969
- AGEN 1994
- Country
- ALOT United States
- AGEN United States
- Employees
- ALOT N/A
- AGEN N/A
- Industry
- ALOT Computer peripheral equipment
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALOT Technology
- AGEN Health Care
- Exchange
- ALOT Nasdaq
- AGEN Nasdaq
- Market Cap
- ALOT 110.1M
- AGEN 97.7M
- IPO Year
- ALOT N/A
- AGEN 2000
- Fundamental
- Price
- ALOT $14.00
- AGEN $4.50
- Analyst Decision
- ALOT
- AGEN Buy
- Analyst Count
- ALOT 0
- AGEN 3
- Target Price
- ALOT N/A
- AGEN $10.00
- AVG Volume (30 Days)
- ALOT 13.2K
- AGEN 346.0K
- Earning Date
- ALOT 12-04-2024
- AGEN 11-05-2024
- Dividend Yield
- ALOT N/A
- AGEN N/A
- EPS Growth
- ALOT 591.76
- AGEN N/A
- EPS
- ALOT 0.83
- AGEN N/A
- Revenue
- ALOT $150,643,000.00
- AGEN $159,630,000.00
- Revenue This Year
- ALOT N/A
- AGEN N/A
- Revenue Next Year
- ALOT N/A
- AGEN $0.04
- P/E Ratio
- ALOT $16.87
- AGEN N/A
- Revenue Growth
- ALOT 0.29
- AGEN 60.67
- 52 Week Low
- ALOT $12.05
- AGEN $4.18
- 52 Week High
- ALOT $18.83
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- ALOT 50.14
- AGEN 40.31
- Support Level
- ALOT $13.70
- AGEN $4.50
- Resistance Level
- ALOT $14.60
- AGEN $4.78
- Average True Range (ATR)
- ALOT 0.54
- AGEN 0.29
- MACD
- ALOT 0.07
- AGEN 0.02
- Stochastic Oscillator
- ALOT 53.85
- AGEN 30.77
About ALOT AstroNova Inc.
AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).